T
Toku Eyes
AI-powered retinal imaging for systemic health assessment
About Toku Eyes
Toku Eyes is a health technology company that utilizes artificial intelligence to analyze retinal images for early detection and risk assessment of chronic diseases. The company was founded in 2018 as a spin-out from the University of Auckland by Associate Professor Ehsan Vaghefi and Dr. David Squirrell. Vaghefi's personal experience with his father's preventable blindness from congenital glaucoma fueled his mission to make disease screening more accessible.
The company's core business revolves around its AI platform that integrates with existing retinal cameras to provide rapid, non-invasive health assessments. This makes screening possible in various point-of-care settings like optometry clinics, primary care, and pharmacies. Toku's business model involves strategic partnerships with major industry players, such as optical retailers and ophthalmic device manufacturers, to deploy its software. For example, partnerships with National Vision and Topcon Healthcare are set to make them significant customers, integrating Toku's platform into their networks.
Toku offers several products. 'BioAge' analyzes biometric markers in the retina to determine a person's biological age as an indicator of overall health. The 'CLAiR' platform assesses cardiovascular disease (CVD) risk and has received Breakthrough Device designation from the U.S. FDA, which expedites its review process. Another product, 'MyKidneyAI', also granted FDA Breakthrough status, screens for chronic kidney disease risk in people with diabetes. These tools are designed to identify at-risk individuals early, allowing for timely preventative interventions.
Since its inception, Toku Eyes has secured significant funding, including a $3.6 million seed round and a US$8 million Series A round in April 2023, bringing its total to over $10.5 million. The company has expanded its team and is focused on commercialization in North America and other global markets, with regulatory approvals already secured in the UK and Europe.
Source: Dealroom company dataNews
Open roles
Toku Eyes in the Auckland ecosystem
The Toku Eyes office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Artemis Capital
Icehouse Ventures
Kera Link International
Callaghan Innovation
Series A2 investors entered at this stage
National Vision
Topcon Healthcare
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Toku Eyes on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Toku Eyes on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

